IGMS Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 57.00%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $356,994.76

IGM Biosciences Insider Trading History Chart

IGM Biosciences Share Price & Price History

^$1.24

▼ -0.04 (-3.13%)

As of 03/28/2025 05:00 PM ET

Days: 30 | 90 | 365

IGM Biosciences Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/14/2025	Misbah Tahir	CFO	Sell	7,329	$1.23	$9,014.67	180,324
3/14/2025	Steven Weber	Insider	Sell	1,701	$1.23	$2,092.23	28,881
1/15/2025	Steven Weber	Insider	Sell	1,122	$1.70	$1,907.40	30,582
12/16/2024	Mary Beth Harler	CEO	Sell	1,708	$7.48	$12,775.84	347,032
12/16/2024	Steven Weber	Insider	Sell	539	$7.48	$4,031.72	31,704
9/13/2024	Fred Schwarzer	CEO	Sell	3,946	$11.54	$45,536.84	250,124
9/13/2024	Misbah Tahir	CFO	Sell	1,487	$11.54	$17,159.98	122,694
9/13/2024	Steven Weber	Insider	Sell	469	$11.54	$5,412.26	25,543
7/25/2024	Julie Hambleton	Director	Sell	15,132	$14.00	$211,848.00	2,000
6/14/2024	Fred Schwarzer	CEO	Sell	4,164	$7.58	$31,563.12	254,070
6/14/2024	Misbah Tahir	CFO	Sell	1,570	$7.58	$11,900.60	88,848
6/14/2024	Steven Weber	Insider	Sell	495	$7.58	$3,752.10	26,012
3/28/2024	Bros. Advisors Lp Baker	Director	Buy	97,473	$9.62	$937,690.26	3,753,480
3/26/2024	Bros. Advisors Lp Baker	Director	Buy	270,000	$8.26	$2,230,200.00	3,638,533
3/13/2024	Fred Schwarzer	CEO	Sell	4,765	$9.88	$47,078.20	220,833
3/13/2024	Misbah Tahir	CFO	Sell	2,897	$9.88	$28,622.36	92,961
3/13/2024	Steven Weber	Insider	Sell	529	$9.88	$5,226.52	26,971
12/15/2023	Bros. Advisors Lp Baker	Director	Buy	288,007	$6.55	$1,886,445.85	3,390,323
12/13/2023	Bros. Advisors Lp Baker	Director	Buy	87,316	$5.96	$520,403.36	2,977,836
12/13/2023	Bruce Keyt	Insider	Sell	7,574	$5.78	$43,777.72	129,551
12/13/2023	Fred Schwarzer	CEO	Sell	17,576	$5.78	$101,589.28	102,848
11/29/2023	Chris H Takimoto	Insider	Sell	1,180	$6.21	$7,327.80	53,562
11/27/2023	Bruce Keyt	Insider	Sell	933	$5.06	$4,720.98	137,125
11/27/2023	Misbah Tahir	CFO	Sell	1,337	$5.06	$6,765.22	49,608
10/2/2023	George Gauthier	Insider	Sell	935	$7.95	$7,433.25	39,082
7/3/2023	George Gauthier	Insider	Sell	936	$9.42	$8,817.12	40,017
6/29/2023	Jakob Haldor Topsoe	Director	Buy	3,500	$9.10	$31,850.00	78,144
6/26/2023	M Kathleen Behrens	Director	Buy	112,500	$8.00	$900,000.00	330,700
5/23/2023	Chris H Takimoto	Insider	Sell	1,259	$12.31	$15,498.29	54,742
4/5/2023	George Gauthier	Insider	Sell	935	$12.60	$11,781.00	33,878
3/14/2023	Chris H Takimoto	Insider	Sell	1,768	$18.73	$33,114.64	28,789
12/19/2022	Misbah Tahir	CFO	Sell	3,801	$20.00	$76,020.00	27,090
12/16/2022	Chris H Takimoto	Insider	Sell	5,430	$18.98	$103,061.40	30,557
12/16/2022	Fred Schwarzer	CEO	Sell	12,369	$18.98	$234,763.62	20,360
12/16/2022	Misbah Tahir	CFO	Sell	2,283	$18.98	$43,331.34	30,891
11/23/2022	Chris H Takimoto	Insider	Sell	877	$21.57	$18,916.89	35,987
11/23/2022	Fred Schwarzer	CEO	Sell	1,258	$21.57	$27,135.06	32,729
11/8/2022	M Kathleen Behrens	Director	Buy	60,000	$17.14	$1,028,400.00	218,200
10/4/2022	Bruce Keyt	Insider	Sell	25,000	$22.84	$571,000.00	39,489
9/29/2022	Michael D Loberg	Director	Buy	5,821	$19.62	$114,208.02	35,305
9/27/2022	Michael D Loberg	Director	Buy	507	$19.99	$10,134.93	23,312
9/8/2022	Bruce Keyt	Insider	Sell	10,000	$19.78	$197,800.00	39,489
9/6/2022	Bruce Keyt	Insider	Sell	5,000	$19.06	$95,300.00	39,489
8/22/2022	Bruce Keyt	Insider	Sell	6,300	$20.71	$130,473.00	39,489
8/19/2022	Bruce Keyt	Insider	Sell	8,700	$22.82	$198,534.00	39,489
5/26/2022	Misbah Tahir	CFO	Sell	950	$17.10	$16,245.00	33,698
5/24/2022	Chris H Takimoto	Insider	Sell	938	$17.10	$16,039.80	36,864
5/20/2022	Jakob Haldor Topsoe	Director	Buy	1,481	$16.00	$23,696.00	73,462
4/6/2022	Bruce Keyt	Insider	Sell	2,500	$25.00	$62,500.00	40,015
4/1/2022	Michael D Loberg	Director	Buy	21,739	$23.00	$499,997.00	2,646
3/30/2022	Bruce Keyt	Insider	Sell	7,500	$28.50	$213,750.00

See Full Table

SEC Filings (Institutional Ownership Changes) for IGM Biosciences (NASDAQ:IGMS)

42.79% of IGM Biosciences stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

IGM Biosciences Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
2/17/2025	Two Sigma Investments LP	107,620	$0.66M	0.0%	+196.7%	0.181%
2/17/2025	Susquehanna Portfolio Strategies LLC	14,385	$88K	0.3%	-52.4%	0.024%
2/17/2025	Sanofi	1,438,975	$8.79M	5.0%	N/A	2.420%
2/17/2025	Redmile Group LLC	2,952,131	$18.04M	1.3%	-3.9%	4.965%
2/17/2025	Millennium Management LLC	83,468	$0.51M	0.0%	-45.3%	0.140%
2/17/2025	D. E. Shaw & Co. Inc.	10,107	$62K	0.0%	-89.7%	0.017%
2/17/2025	Cubist Systematic Strategies LLC	30,148	$0.18M	0.0%	N/A	0.051%
2/14/2025	Susquehanna Fundamental Investments LLC	36,369	$0.22M	0.0%	N/A	0.061%
2/14/2025	Price T Rowe Associates Inc. MD	3,568,999	$21.81M	0.0%	-11.1%	6.002%
2/13/2025	Renaissance Technologies LLC	75,800	$0.46M	0.0%	+14.0%	0.127%
2/13/2025	Rhenman & Partners Asset Management AB	126,064	$0.77M	0.1%	-32.0%	0.212%
2/12/2025	Geode Capital Management LLC	409,133	$2.50M	0.0%	+3.4%	0.688%
2/6/2025	Charles Schwab Investment Management Inc.	157,843	$0.96M	0.0%	+6.4%	0.265%
1/24/2025	China Universal Asset Management Co. Ltd.	7,226	$44K	0.0%	N/A	0.012%
11/19/2024	Barclays PLC	21,554	$0.36M	0.0%	+48.4%	0.036%
11/16/2024	Geode Capital Management LLC	395,799	$6.55M	0.0%	+7.6%	0.667%
11/15/2024	Barclays PLC	21,554	$0.36M	0.0%	+48.4%	0.036%
11/15/2024	Wellington Management Group LLP	98,339	$1.63M	0.0%	+42.6%	0.166%
11/15/2024	State Street Corp	469,790	$7.77M	0.0%	+2.7%	0.792%
11/15/2024	Baker BROS. Advisors LP	4,092,310	$67.69M	0.7%	+0.0%	6.899%
11/14/2024	MetLife Investment Management LLC	8,997	$0.15M	0.0%	N/A	0.015%
11/13/2024	The Manufacturers Life Insurance Company	74,612	$1.23M	0.0%	+8.2%	0.126%
11/12/2024	Charles Schwab Investment Management Inc.	148,402	$2.46M	0.0%	+12.1%	0.250%
11/7/2024	Quest Partners LLC	1,645	$27K	0.0%	-86.2%	0.003%
11/5/2024	GSA Capital Partners LLP	56,754	$0.94M	0.1%	-8.4%	0.096%
10/10/2024	Exchange Traded Concepts LLC	10,572	$0.18M	0.0%	-50.4%	0.018%
8/19/2024	Point72 Asset Management L.P.	27,246	$0.19M	0.0%	N/A	0.046%
8/15/2024	Susquehanna Fundamental Investments LLC	16,028	$0.11M	0.0%	-42.2%	0.027%
8/15/2024	The Manufacturers Life Insurance Company	68,929	$0.47M	0.0%	-2.2%	0.117%
8/15/2024	AQR Capital Management LLC	12,230	$84K	0.0%	N/A	0.021%
8/14/2024	Marshall Wace LLP	107,267	$0.74M	0.0%	+51.6%	0.182%
8/12/2024	XTX Topco Ltd	20,408	$0.14M	0.0%	+70.9%	0.035%
8/9/2024	Renaissance Technologies LLC	108,693	$0.75M	0.0%	+126.0%	0.184%
8/9/2024	Dimensional Fund Advisors LP	37,034	$0.25M	0.0%	-6.1%	0.063%
8/9/2024	Bruce & Co. Inc.	100,000	$0.69M	0.2%	+53.8%	0.169%
8/6/2024	Quest Partners LLC	11,913	$82K	0.0%	+71.4%	0.020%
8/3/2024	TD Asset Management Inc	164,472	$1.13M	0.0%	+3.4%	0.279%
8/1/2024	Rhumbline Advisers	22,726	$0.16M	0.0%	+13.1%	0.039%
7/26/2024	Bank of New York Mellon Corp	53,980	$0.37M	0.0%	+8.9%	0.091%
5/17/2024	Artal Group S.A.	3,080,422	$29.73M	0.8%	-0.6%	5.240%
5/16/2024	Jacobs Levy Equity Management Inc.	78,580	$0.76M	0.0%	N/A	0.134%
5/16/2024	Redmile Group LLC	3,072,478	$29.65M	1.1%	+3.4%	5.226%
5/15/2024	Baker BROS. Advisors LP	4,088,322	$39.45M	0.5%	+10.8%	6.954%
5/15/2024	Price T Rowe Associates Inc. MD	3,888,023	$37.52M	0.0%	+19.3%	6.614%
5/14/2024	EntryPoint Capital LLC	15,801	$0.15M	0.1%	N/A	0.027%
5/10/2024	Vanguard Group Inc.	853,658	$8.24M	0.0%	-4.8%	1.452%
5/7/2024	Susquehanna Fundamental Investments LLC	27,731	$0.27M	0.0%	N/A	0.047%
2/14/2024	Pennant Investors LP	64,900	$0.54M	0.1%	N/A	0.111%
2/14/2024	Pale Fire Capital SE	11,601	$96K	0.0%	-7.9%	0.020%
2/12/2024	Bruce & Co. Inc.	65,000	$0.54M	0.2%	-45.8%	0.111%
2/8/2024	Panagora Asset Management Inc.	30,273	$0.25M	0.0%	N/A	0.052%
1/25/2024	Nisa Investment Advisors LLC	3,900	$32K	0.0%	+7,258.5%	0.007%
1/5/2024	Exchange Traded Concepts LLC	19,048	$0.16M	0.0%	+34.0%	0.033%
12/7/2023	Hudson Bay Capital Management LP	124,260	$1.04M	0.0%	N/A	0.213%
11/15/2023	GSA Capital Partners LLP	133,276	$1.11M	0.1%	+24.7%	0.228%
11/14/2023	Pale Fire Capital SE	12,601	$0.11M	0.0%	N/A	0.022%
11/13/2023	DekaBank Deutsche Girozentrale	6,303	$50K	0.0%	N/A	0.011%
11/9/2023	Rhenman & Partners Asset Management AB	750,000	$6.26M	0.5%	+275.0%	1.285%
10/27/2023	TD Asset Management Inc	83,452	$0.70M	0.0%	+100.0%	0.143%
10/24/2023	Bank of New York Mellon Corp	52,068	$0.44M	0.0%	-27.9%	0.089%
8/15/2023	RA Capital Management L.P.	937,500	$8.65M	0.2%	N/A	1.606%
8/14/2023	Great Point Partners LLC	500,000	$4.62M	0.9%	N/A	0.857%
8/14/2023	Prelude Capital Management LLC	19,675	$0.18M	0.0%	N/A	0.034%
8/11/2023	Artal Group S.A.	2,522,244	$23.28M	0.7%	+0.5%	5.855%
8/11/2023	Rhenman & Partners Asset Management AB	200,000	$1.85M	0.2%	+110.5%	0.464%
8/9/2023	TD Asset Management Inc	41,726	$0.39M	0.0%	+120.9%	0.097%
8/8/2023	Candriam S.C.A.	175,008	$1.62M	0.0%	-6.8%	0.406%
8/4/2023	Maven Securities LTD	24,800	$0.23M	0.0%	N/A	0.058%
7/20/2023	Exchange Traded Concepts LLC	13,800	$0.13M	0.0%	N/A	0.032%
5/12/2023	Rhenman & Partners Asset Management AB	95,000	$1.62M	0.2%	+90.0%	0.221%
5/11/2023	ExodusPoint Capital Management LP	59,650	$0.82M	0.0%	+26.7%	0.138%
5/9/2023	Tower Research Capital LLC TRC	6,122	$84K	0.0%	+923.7%	0.014%
4/14/2023	Raymond James & Associates	41,348	$0.57M	0.0%	-2.7%	0.096%
2/15/2023	Endurant Capital Management LP	30,320	$0.52M	0.2%	N/A	0.071%
2/15/2023	Alkeon Capital Management LLC	833,241	$14.17M	0.1%	-13.3%	1.945%
2/13/2023	GSA Capital Partners LLP	29,861	$0.51M	0.1%	+64.3%	0.070%
2/13/2023	Rhenman & Partners Asset Management AB	50,000	$0.85M	0.1%	N/A	0.117%
2/10/2023	New York Life Investment Management LLC	21,167	$0.36M	0.0%	+12.4%	0.049%
2/10/2023	Schroder Investment Management Group	26,833	$0.46M	0.0%	N/A	0.063%
2/9/2023	Victory Capital Management Inc.	90,200	$1.53M	0.0%	+12.1%	0.211%
2/8/2023	Raymond James & Associates	42,516	$0.72M	0.0%	+4.6%	0.099%
2/8/2023	Swiss National Bank	24,500	$0.42M	0.0%	+7.9%	0.057%
11/15/2022	Marshall Wace LLP	246,689	$5.61M	0.0%	-2.4%	0.576%
11/14/2022	Delphia USA Inc.	10,185	$0.23M	0.3%	N/A	0.024%
11/14/2022	PDT Partners LLC	13,126	$0.30M	0.0%	-9.3%	0.031%
11/10/2022	ExodusPoint Capital Management LP	25,485	$0.58M	0.0%	N/A	0.060%
11/7/2022	Quantbot Technologies LP	3,600	$81K	0.0%	N/A	0.008%
11/7/2022	Jump Financial LLC	26,900	$0.61M	0.0%	+3.2%	0.063%
11/3/2022	Barclays PLC	1,951	$44K	0.0%	-78.8%	0.005%
11/2/2022	Victory Capital Management Inc.	80,450	$1.83M	0.0%	-1.0%	0.189%
10/31/2022	SG Americas Securities LLC	6,322	$0.14M	0.0%	N/A	0.015%
10/26/2022	Allspring Global Investments Holdings LLC	2,729	$62K	0.0%	N/A	0.006%
10/25/2022	Raymond James & Associates	40,633	$0.92M	0.0%	+4.9%	0.096%
8/19/2022	Eagle Bay Advisors LLC	41,635	$0.75M	0.5%	+19.5%	0.098%
8/16/2022	Woodline Partners LP	200,047	$3.61M	0.1%	-50.4%	0.470%
8/15/2022	Alpha Paradigm Partners LLC	8,939	$0.16M	0.1%	N/A	0.021%
8/12/2022	Virtus ETF Advisers LLC	7,267	$0.13M	0.0%	+32.9%	0.017%
8/12/2022	Ensign Peak Advisors Inc	1,480	$27K	0.0%	-96.8%	0.003%
8/9/2022	Swiss National Bank	21,500	$0.39M	0.0%	+16.2%	0.051%
8/5/2022	State Board of Administration of Florida Retirement System	14,748	$0.27M	0.0%	N/A	0.035%

Data available starting January 2016

See Full Table

IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases. IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.

Today's Range

Now: $1.24

$1.22

$1.30

50 Day Range

MA: $1.40

$1.19

$1.77

52 Week Range

Now: $1.24

$1.15

$22.50

Volume

124,722 shs

Average Volume

339,690 shs

Market Capitalization

$74.12 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.37

Who are the company insiders with the largest holdings of IGM Biosciences?: IGM Biosciences' top insider shareholders include:
Bros Advisors Lp Baker (Director)
Mary Beth Harler (CEO)
M Kathleen Behrens (Director)
Fred Schwarzer (CEO)
Misbah Tahir (CFO)
Bruce Keyt (Insider)
Jakob Haldor Topsoe (Director)
Chris H Takimoto (Insider)
George Gauthier (Insider)
Steven Weber (Insider)
Julie Hambleton (Director)
Learn More about top insider investors at IGM Biosciences.
Who are the major institutional investors of IGM Biosciences?: IGM Biosciences' top institutional shareholders include:
Price T Rowe Associates Inc. MD — 6.00%
Redmile Group LLC — 4.96%
Sanofi — 2.42%
Geode Capital Management LLC — 0.69%
Charles Schwab Investment Management Inc. — 0.27%
Rhenman & Partners Asset Management AB — 0.21%
Learn More about top institutional investors of IGM Biosciences stock.
Which institutional investors are selling IGM Biosciences stock?: During the last quarter, IGMS stock was sold by these institutional investors:
Price T Rowe Associates Inc. MD
Redmile Group LLC
D. E. Shaw & Co. Inc.
Millennium Management LLC
Rhenman & Partners Asset Management AB
Susquehanna Portfolio Strategies LLC
Within the previous year, company insiders that have sold IGM Biosciences company stock include:
Bros Advisors Lp Baker (Director)
Mary Beth Harler (CEO)
M Kathleen Behrens (Director)
Fred Schwarzer (CEO)
Misbah Tahir (CFO)
Learn More investors selling IGM Biosciences stock.
Which institutional investors are buying IGM Biosciences stock?: Within the previous quarter, IGMS stock was purchased by institutional investors including:
Sanofi
Two Sigma Investments LP
Susquehanna Fundamental Investments LLC
Cubist Systematic Strategies LLC
Geode Capital Management LLC
Charles Schwab Investment Management Inc.
Renaissance Technologies LLC
China Universal Asset Management Co. Ltd.
Within the last year, these company insiders have bought IGM Biosciences stock:
Bros Advisors Lp Baker (Director)
Mary Beth Harler (CEO)
M Kathleen Behrens (Director)
Learn More investors buying IGM Biosciences stock.